Literature DB >> 31898004

Assessing the qualitative and quantitative impacts of simple two-class vs multiple tissue-class MR-based attenuation correction for cardiac PET/MR.

Philip M Robson1, Vittoria Vergani2,3, Thomas Benkert4,5, Maria Giovanna Trivieri2,6, Nicolas A Karakatsanis2,7, Ronan Abgral8, Marc R Dweck9, Pedro R Moreno6, Jason C Kovacic6, Kai Tobias Block4,5, Zahi A Fayad2.   

Abstract

BACKGROUND: Hybrid PET/MR imaging has significant potential in cardiology due to its combination of molecular PET imaging and cardiac MR. Multi-tissue-class MR-based attenuation correction (MRAC) is necessary for accurate PET quantification. Moreover, for thoracic PET imaging, respiration is known to lead to misalignments of MRAC and PET data that result in PET artifacts. These factors can be addressed by using multi-echo MR for tissue segmentation and motion-robust or motion-gated acquisitions. However, the combination of these strategies is not routinely available and can be prone to errors. In this study, we examine the qualitative and quantitative impacts of multi-class MRAC compared to a more widely available simple two-class MRAC for cardiac PET/MR. METHODS AND
RESULTS: In a cohort of patients with cardiac sarcoidosis, we acquired MRAC data using multi-echo radial gradient-echo MR imaging. Water-fat separation was used to produce attenuation maps with up to 4 tissue classes including water-based soft tissue, fat, lung, and background air. Simultaneously acquired 18F-fluorodeoxyglucose PET data were subsequently reconstructed using each attenuation map separately. PET uptake values were measured in the myocardium and compared between different PET images. The inclusion of lung and subcutaneous fat in the MRAC maps significantly affected the quantification of 18F-fluorodeoxyglucose activity in the myocardium but only moderately altered the appearance of the PET image without introduction of image artifacts.
CONCLUSION: Optimal MRAC for cardiac PET/MR applications should include segmentation of all tissues in combination with compensation for the respiratory-related motion of the heart. Simple two-class MRAC is adequate for qualitative clinical assessment.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  MRAC; PET/MR; attenuation correction; cardiac sarcoidosis; nuclear cardiology

Mesh:

Substances:

Year:  2020        PMID: 31898004      PMCID: PMC7329599          DOI: 10.1007/s12350-019-02002-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  19 in total

1.  Hybrid PET/MR imaging of the heart: feasibility and initial results.

Authors:  Felix Nensa; Thorsten D Poeppel; Karsten Beiderwellen; Juliane Schelhorn; Amir A Mahabadi; Raimund Erbel; Philipp Heusch; Kai Nassenstein; Andreas Bockisch; Michael Forsting; Thomas Schlosser
Journal:  Radiology       Date:  2013-05-07       Impact factor: 11.105

2.  Respiratory-resolved MR-based attenuation correction for motion-compensated cardiac PET-MR.

Authors:  Christoph Kolbitsch; Radhouene Neji; Matthias Fenchel; Andrew Mallia; Paul Marsden; Tobias Schaeffter
Journal:  Phys Med Biol       Date:  2018-06-27       Impact factor: 3.609

Review 3.  Cardiovascular PET/MR imaging: Quo Vadis?

Authors:  Thomas Hellmut Schindler
Journal:  J Nucl Cardiol       Date:  2016-09-22       Impact factor: 5.952

4.  Simple proton spectroscopic imaging.

Authors:  W T Dixon
Journal:  Radiology       Date:  1984-10       Impact factor: 11.105

5.  MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods.

Authors:  Matthias Hofmann; Ilja Bezrukov; Frederic Mantlik; Philip Aschoff; Florian Steinke; Thomas Beyer; Bernd J Pichler; Bernhard Schölkopf
Journal:  J Nucl Med       Date:  2011-08-09       Impact factor: 10.057

6.  MR-based attenuation correction for cardiac FDG PET on a hybrid PET/MRI scanner: comparison with standard CT attenuation correction.

Authors:  Jan Vontobel; Riccardo Liga; Mathias Possner; Olivier F Clerc; Fran Mikulicic; Patrick Veit-Haibach; Edwin E G W Ter Voert; Tobias A Fuchs; Julia Stehli; Aju P Pazhenkottil; Dominik C Benz; Christoph Gräni; Oliver Gaemperli; Bernhard Herzog; Ronny R Buechel; Philipp A Kaufmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-20       Impact factor: 9.236

7.  Hybrid ZTE/Dixon MR-based attenuation correction for quantitative uptake estimation of pelvic lesions in PET/MRI.

Authors:  Andrew P Leynes; Jaewon Yang; Dattesh D Shanbhag; Sandeep S Kaushik; Youngho Seo; Thomas A Hope; Florian Wiesinger; Peder E Z Larson
Journal:  Med Phys       Date:  2017-03       Impact factor: 4.071

8.  Free-breathing volumetric fat/water separation by combining radial sampling, compressed sensing, and parallel imaging.

Authors:  Thomas Benkert; Li Feng; Daniel K Sodickson; Hersh Chandarana; Kai Tobias Block
Journal:  Magn Reson Med       Date:  2016-09-09       Impact factor: 4.668

9.  Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.

Authors:  Marc R Dweck; Ronan Abgral; Maria Giovanna Trivieri; Philip M Robson; Nicolas Karakatsanis; Venkatesh Mani; Anna Palmisano; Marc A Miller; Anuradha Lala; Helena L Chang; Javier Sanz; Johanna Contreras; Jagat Narula; Valentin Fuster; Maria Padilla; Zahi A Fayad; Jason C Kovacic
Journal:  JACC Cardiovasc Imaging       Date:  2017-06-14

10.  Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion.

Authors:  Claes Nøhr Ladefoged; Adam Espe Hansen; Sune Høgild Keller; Søren Holm; Ian Law; Thomas Beyer; Liselotte Højgaard; Andreas Kjær; Flemming Littrup Andersen
Journal:  EJNMMI Phys       Date:  2014-12-14
View more
  1 in total

1.  Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.

Authors:  Aruki Tanaka; Tetsuro Sekine; Edwin E G W Ter Voert; Konstantinos G Zeimpekis; Gaspar Delso; Felipe de Galiza Barbosa; Geoffrey Warnock; Shin-Ichiro Kumita; Patrick Veit Haibach; Martin Huellner
Journal:  Front Med (Lausanne)       Date:  2022-03-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.